Top news
All coverage
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
By Julie Steenhuysen & Deena Beasley
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
By Berkeley Lovelace & Berkeley Lovelace Jr.
Biogen's aducanumab crosses FDA finish line just in time to save its business
By Noah Higgins-Dunn
New Alzheimer’s drug is 1st of its kind to be FDA approved
By Sony Salzman & Deepak Ramanathan
In controversial decision, FDA approves first new Alzheimer's disease drug in nearly 20 years
By Jacqueline Howard
FDA approves first drug intended to slow cognitive decline caused by Alzheimer's disease
By Laurie McGinley
Alzheimer's drug from Biogen wins US approval
By Nikou Asgari
Alzheimer's Drug Poses a Dilemma for the F.D.A. (Published 2021)
By Pam Belluck & Rebecca Robbins
FDA Approves First New Alzheimer's Drug in Nearly Two Decades
By Joseph Walker
Aducanumab: FDA Approves Controversial Alzheimer's Drug
By Scott Hensley
Biogen shares surge 38% after FDA approves Alzheimer's drug, the first new therapy for the disease in nearly two decades
By Berkeley Lovelace & Berkeley Lovelace Jr.
Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense (Published 2021)
By Pam Belluck & Rebecca Robbins
F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works (Published 2021)
By Pam Belluck & Rebecca Robbins